Market: NASD |
Currency: USD
Address: 20 Park Plaza
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
📈 CervoMed Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$21.50
-
Upside/Downside from Analyst Target:
124.90%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.666667 |
- |
2023-08-17 |
- |
Stock split |
|
Total Amount for 2023: $0.666667 |
| 2022 |
- |
$0.020000 |
- |
2022-04-19 |
- |
Stock split |
|
Total Amount for 2022: $0.020000 |
| 2018 |
- |
$0.066667 |
- |
2018-12-14 |
- |
Stock split |
|
Total Amount for 2018: $0.066667 |
| 2016 |
- |
$0.100000 |
- |
2016-08-19 |
- |
Stock split |
|
Total Amount for 2016: $0.100000 |
📅 Earnings & EPS History for CervoMed Inc.
| Date | Reported EPS |
|---|
| 2025-08-08 | -0.7 |
| 2025-05-12 | -0.56 |
| 2025-03-17 | -0.8 |
| 2024-11-12 | -0.55 |
| 2024-08-09 | -0.27 |
| 2024-05-14 | -0.41 |
| 2024-03-29 | -0.95 |
| 2023-11-13 | 0.65 |
📰 Related News & Research
No related articles found for "cervomed inc".
